Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kadmon, a Sanofi Company
Duration per participants is Day 1 up to 30 days after participant is treated with the last dose of study drug.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy participants between the ages of 18 and 55 years, inclusive.
Able to provide written informed consent prior to the performance of any study specific procedures.
Body mass index (BMI) range of 19-30 kilogram per square meter (kg/m2), inclusive.
You may not be if
Participants are excluded from the study if any of the following criteria apply:
Past or present disease that is judged by the investigator to have the potential to interfere with the study procedures, compromise safety, or affect the PK evaluations.
Known sensitivity to Rho-associated coiled-coil containing serine/threonine protein kinases (ROCK2) inhibitor agents or to any of the constituents of the KD025 formulation.
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
